

TECHNICAL DATA SHEET

CD56 (MY31)

Analyte Specific Reagent (ASR)*

Туре	Number	Volume per	Total volume	Catalog number
	of tests	test (μL)	(μL)	
FITC	50	5	250	4106012
	100	5	500	4106015
APC	50	5	250	4106042
	100	5	500	4106045
PE	50	5	250	4106022
	100	5	500	4106025
PerCP-Cyanine5.5	50	5	250	4106062
	100	5	500	4106065
APC-Cyanine7	50	5	250	4106092
	100	5	500	4106095
PE-Cyanine7	50	5	250	4106082
	100	5	500	4106085
PE-CF594	50	5	250	4106202
	100	5	500	4106205
APC-iFluor [™] 700	50	5	250	4106172
	100	5	500	4106175
iFluor™647	50	5	250	4106122
	100	5	500	4106125

Antigen: CD56

 $\begin{array}{ll} \mbox{Immunogen:} & \mbox{KG1a cell line} \\ \mbox{Host/lsotype:} & \mbox{Mouse lgG1, } \kappa \\ \end{array}$

Reactivity: Human

Purity: >90% pure tested via polyacrylamide gel electrophoresis (PAGE)

Formulation: PBS, pH7.2, 0.09% NaN₃ and 0.2% (w/v) BSA

Storage: Store at 2-8°C and protected from prolonged exposure to light. **Do not freeze.**

Applications: Flow Cytometry.

Antigen Information

The clone MY31, a mouse antibody, binds to the human 140-kDa glycoprotein, an isoform of neural cell adhesion molecule (NCAM) known as CD56. CD56 and CD16 expressing lymphocytes are primarily considered as human NK cells and NK-T cells. A subset of CD56+ NK cells plays a unique functional role in the innate immune response as the primary source of NK cell—derived immunoregulatory cytokines, regulated in part by differential monokine production. CD56 is expressed in normal and as well as neoplastic human neuroendocrine tissues, certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias. Additionally, increased CD56+ lymphocyte subsets in peripheral blood are a significant predictive or prognostic factor in metastatic breast cancer.

References

- 1. Lanier LL, et al. J Immunol. 1991. 146(12):4421-4426.
- 2. Jin L, et al. Am J Pathol. 1991 Apr;138(4):961-9.
- 3. Megan AC, et al. Blood. 97:3146-3151.
- 4. Nakano-Akamatsu S, et al. Int.J. Hematol. 2007. 86:348-351.
- 5. Yang J, et al. Cancer Med. 2019. DOI: 10.1002/cam4.1891

^{*}Analyte Specific Reagent. The analytical and performance characteristics of this ASR product are not established.